Overall, these findings demonstrated that Tet ameliorates NAFLD by modulating lipid metabolism and apoptosis through activation of the PI3K/AKT/STAT3 signaling pathway, providing integrated computational, genetic, and experimental evidence for its potential as a therapeutic agent. This evidence concerns the gene STAT3 and metabolic dysfunction-associated steatotic liver disease.